Edwards Lifesciences (EW) Earning Somewhat Favorable News Coverage, Report Finds
Media stories about Edwards Lifesciences (NYSE:EW) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Edwards Lifesciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.2696884704141 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- NVIDIA Corporation (NVDA) Once Again Win Street Race- Edwards Lifesciences Corporation (EW) – Investing News Update (investingbizz.com)
- Basic Trading Data for Edwards Lifesciences Corporation (EW) – Market Movers (financialqz.com)
- Kaman Corporation (KAMN) Ex-Dividend Date Scheduled for December 18, 2017 – Nasdaq (nasdaq.com)
- Edwards Lifesciences Corporation (NYSE:EW) – Which Option is Best? – Buy or Sell – Nasdaq Journal (press release) (nasdaqjournal.com)
- Zacks: Analysts Expect Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $862.69 Million (americanbankingnews.com)
A number of research firms recently issued reports on EW. Cowen set a $135.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Sunday, December 10th. BMO Capital Markets reissued a “buy” rating and issued a $137.00 price target on shares of Edwards Lifesciences in a research note on Friday, December 8th. Canaccord Genuity reissued a “buy” rating and issued a $137.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. Deutsche Bank decreased their price target on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research note on Thursday, October 26th. Finally, Morgan Stanley decreased their price target on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research note on Thursday, October 26th. Six equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Edwards Lifesciences presently has an average rating of “Buy” and a consensus price target of $126.43.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences had a return on equity of 22.36% and a net margin of 20.71%. Edwards Lifesciences’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.68 EPS. sell-side analysts forecast that Edwards Lifesciences will post 3.76 EPS for the current fiscal year.
Edwards Lifesciences announced that its board has approved a share buyback plan on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.
In related news, Director Schack Wesley W. Von sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total value of $104,150.00. Following the sale, the director now owns 2,622 shares in the company, valued at $273,081.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Larry L. Wood sold 18,960 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $114.58, for a total transaction of $2,172,436.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 139,580 shares of company stock worth $14,887,125. Corporate insiders own 2.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/edwards-lifesciences-ew-earning-somewhat-favorable-news-coverage-report-finds/1770191.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.